The data available on secondary prevention care variations in women with premature and extremely premature atherosclerotic cardiovascular disease (ASCVD) is not clear. The objective of this study is to analyze sex-based differences in antiplatelet agents, statins, and statin adherence in patients with premature and extremely premature ASCVD.
This multicenter, cross-sectional, nationwide study included a total of 10,413 women and 123,187 men with premature ASCVD and 1,340 women and 8,145 men with extremely premature ASCVD, including ischemic heart disease (IHD), peripheral arterial disease (PAD), and ischemic cerebrovascular disease (ICVD). The primary outcomes of the study were antiplatelet use, statin use, high-intensity statin (HIS) use, and statin adherence.
The findings suggested that when compared with men, women with premature ASCVD had a lower proportion of Asian patients (0.5% vs. 0.7%) and White patients (56.1% vs. 68.1%) and a higher promotion of African American patients (36.1% vs. 23.8%). The extremely premature group had a lower proportion of White patients and a higher proportion of African American patients. Women with IHD, PAD, ICVD received less antiplatelet therapy, HIS, and any statin than men.
The research concluded that women with premature and extremely premature ASCVD were less adherent to statins and received less antiplatelet therapy than men.
Ref: https://jamanetwork.com/journals/jamacardiology/article-abstract/2778578?resultClick=1
